Randomized trial · people

Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For people with obesity and prediabetes, this trial shows weight loss held up over about 3 years on tirzepatide and far fewer people developed type 2 diabetes than on placebo.

Kind
Randomized trial
Studied in
People
Number studied
1032
Published
2025
Journal
N Engl J Med

What they tested

The team tested whether 3 years of weekly tirzepatide lowers weight and delays type 2 diabetes in people with obesity and prediabetes, and looked at its safety.

How the study was done

A phase 3, double-blind, randomized, placebo-controlled trial that enrolled 2539 people with obesity. This analysis covers the 1032 who also had prediabetes and got once-weekly tirzepatide at 5 mg, 10 mg or 15 mg, or placebo (an inactive comparison), for 176 weeks, then 17 weeks off treatment.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 176 weeks, average body weight changed by -12.3% in the 5 mg arm, -18.7% in the 10 mg arm and -19.7% in the 15 mg arm, versus -1.3% on placebo. Type 2 diabetes was diagnosed in 1.3% of the tirzepatide groups versus 13.3% of the placebo group (hazard ratio 0.07, 95% CI 0.0 to 0.1). After 17 weeks off treatment, the figures were 2.4% versus 13.7% (hazard ratio 0.12, 95% CI 0.1 to 0.2). Apart from COVID-19, the most common side effects were gastrointestinal, mostly mild to moderate and mainly in the first 20 weeks while doses were being raised, and the trial found no new safety signals.

What it doesn’t show

This covers only the participants who had prediabetes, and it followed them for 17 weeks after stopping, so it does not show what happens over a longer time off the drug. The trial was funded by Eli Lilly.

The paper

Jastreboff et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo